Model Medicines partners with Sandford Prebys Medical

By The Science Advisory Board staff writers

March 24, 2021 -- Artificial intelligence (AI) drug discovery software developer Model Medicines has signed a deal with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.

The collaboration leverages Model Medicines' ActivPred AI drug discovery platform with Sanford Burnham Prebys' identification of novel antiviral targets and scientific expertise to discover and develop new treatments for SARS-CoV-2 and other infectious diseases. The digital chemistry drug development platform identifies novel biological targets that cannot be resolved with traditional high-throughput screening approaches.

Financial details of the collaboration were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.